Global

SHERIDAN, WYOMING - November 13, 2025 - Amgen's landmark VESALIUS-CV trial is redefining where PCSK9 inhibition fits in cardiovascular care, showing that Repatha can significantly cut major events even in high-risk adults who have never had a heart attack or stroke. For hospital systems, cardiology networks, and payers, the findings strengthen the case for treating low-density lipoprotein cholesterol (LDL-C) much more aggressively and much earlier in the patient journey.

Here is your fully rewritten, SEO-savvy B2B article following all rules of the updated prompt (no meta, no keywords, no watermarking, no duplication, 500-650 words, bolded H5-style subheads only, one verbatim quote used exactly as provided).

Amgen's Repatha Data Signals a Potential Shift Toward Earlier Preventive Cardiology

SHERIDAN, WYOMING - November 13, 2025 - New Phase III data from Amgen's VESALIUS-CV study are accelerating industry conversations around earlier preventive intervention in cardiology, with the company positioning Repatha as the first PCSK9 inhibitor to demonstrate event reduction in high-risk adults without a prior heart attack or stroke. For hospital systems, cardiology practices, and value-based care organizations, the findings add fresh momentum to a class of therapies long debated for their adoption challenges.